.png "Mizuho Securities Reaffirms Their Hold Rating on Biogen Inc (BIIB)")
Mizuho Securities analyst Salim Syed maintained a Hold rating on Biogen Inc (BIIB) today and set a price target of $235. The company’s shares closed on Thursday at $226.39, close to its 52-week low of $216.12.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.6% and a 35.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.
Currently, the analyst consensus on Biogen Inc is a Hold with an average price target of $260.91, implying a 15.2% upside from current levels. In a report issued on April 10, Raymond James also initiated coverage with a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $388.67 and a one-year low of $216.12. Currently, Biogen Inc has an average volume of 2.25M.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BIIB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Read More on BIIB:
